U.S. Department of Health and Human Services
Workshop on Immune System Engineering for Targeted Tolerance in Type 1 Diabetes (T1D)

Workshop on Immune System Engineering for Targeted Tolerance in Type 1 Diabetes (T1D)

11/1/2017 5:30 PM
11/2/2017 6:30 PM
(800) 228-9290
​​Program Content
Lisa Spain, Ph.D.
T: 301-451-9871
E: spainl@mail.nih.gov

Meeting Logistics

John Hare
The Scientific Consulting Group, Inc.
T: 301-670-4990
E: jhare@scgcorp.com
North Bethesda
Bethesda North Marriott Hotel & Conference Center

Event Details


Type 1 diabetes results in part from the autoimmune destruction of the insulin-producing pancreatic beta cells. It may be possible to change the course of the disease by interfering with autoimmune pathogenesis and re-establishing tolerance. For example, immune responses may be de-activated specifically and safely through the development of tolerizing vaccines, or through the direct manipulation of regulatory and other cells for applications in cell therapy.

In this Workshop, scientists from diverse fields (bioengineering, microbiomics, cancer immunology, etc.) will come together with diabetes experts to discuss how new knowledge, tools and technologies may be applied to reverse autoimmunity.

Meeting Objectives

Examples of topics for discussion include:

  1. Development of safe tolerizing adjuvants or delivery systems
    1. The development of materials that deliver specific antigens in ways that direct the immune response towards active tolerance.
    2. Understanding of anti-inflammatory or autoimmune mechanisms that are specific and can be manipulated or targeted.
  2. Engineer immune system cells for use as highly specific therapeutics
    1. Re-directing effector immune cells to eliminate pathogenic cell types
    2. Re-directing or strengthening immune regulatory cells to dampen the overactive immune system at sites of autoimmune damage.

Registration Deadline

October 15, 2017

This meeting is being held in conjunction with the Autoantigens Discovery and Characterization in Type 1 Diabetes workshop.​


November 1, 2017

5:30 p.m. – 5:35 p.m. Call to Order and Introduction
Lisa Spain, NIDDK, Bethesda
5:35 p.m. – 6:30 p.m. Keynote Opening Lecture
Jerry Nepom, Benaroya at VMU, Seattle
6:30 p.m. – 8:00 p.m. Dinner (TBD)

November 2, 2017

8:30 a.m. – 8:35 a.m. Call to order
Lisa Spain

Session I

Lessons Learned in Promoting Tolerance in Type 1 Diabetes

8:35 a.m. – 8:45 a.m. Introduction
Qizhi Tang, University of California, San Francisco
8:45 a.m. – 9:10 a.m. Clinical Trials With Proinsulin Peptide For Tolerization
Mark Peakman, King’s College, London
9:10 a.m. – 9:30 a.m. Type 1 Diabetes TrialNet: Past, Present, Future
Carla Greenbaum, Benaroya, Seattle
9:30 a.m. – 10:00 a.m. Features of Human T1D—nPOD findings Thus Far
Todd Brusko (PDF, 125 KB), University of Florida, Gainesville
10:00 a.m. – 10:15 a.m. Break
10:15 a.m. – 10:45 a.m. Gut Microbiome and Tolerance
Daniel Graham (PDF, 106 KB), Broad Institute, Cambridge
10:45 a.m. – 11:15 a.m. Microbial Metabolites
CR Mackay, Monash University, Melbourne
11:15 a.m. – 11:45 a.m. Panel Discussion: Opportunities, Gaps, Challenges
Moderators: Bart Roep & Eddie James
11:45 a.m. – 12:30 p.m. Lunch (on your own)

Session II

Manipulating the Immune System for Tolerance: Adjuvants and Cellular Engineering

12:30 p.m. – 1:00 p.m. Introduction
Nik Petrovsky, Flinders University, Flinders
1:00 p.m. – 1:30 p.m. Celiac Peptides
Bob Anderson, ImmusanT, Boston
1:30 p.m. – 2:00 p.m. Biomaterials for Immunological Tolerance Technology for Preventing Immunity
Jeff Hubbell, University of Chicago, Chicago
2:00 p.m. – 2:30 p.m. Therapies to Promote Tregs
Allison Bayer (PDF, 122 KB), U Miami, Miami
2:30 p.m. – 2:45 p.m. Break
2:45 p.m. – 3:15 p.m. CAR-T Cancer Immunotherapy and Beyond
Michel Sadelain, Memorial Sloan-Kettering, New York
3:15 p.m. – 3:45 p.m. Cell Therapy With Genetically Engineered Regulatory T Cells to Induce Immunological Tolerance
Maria-Grazia Roncarolo, Stanford University, Palo Alto
3:45 p.m. – 4:15 p.m. CAR-Treg Immunotherapy
David Scott, Uniformed Services University, Bethesda
4:15 p.m. – 4:30 p.m. Break
4:30 p.m. – 5:00 p.m. Outlook for Promoting Antigen Specific Tolerance
Matthias von Herrath (PDF, 76.8 KB), Novo Nordisk/LIAI, Seattle/La Jolla
5:00 p.m. – 5:30 p.m. Discussion Panel: Opportunities, Gaps, Challenges
Moderators: Alice Tomei (PDF, 236 KB) & Aaron Michels
5:30 p.m. Concluding Remarks and Overall Discussion


Hotel Accommodations

Bethesda North Marriott Hotel & Conference Center
5701 Marinelli Road
North Bethesda, MD 20852
Phone:  (301) 822-9200 or (800) 228-9290

Website:  www.marriott.com/hotels/travel/wasbn-bethesda-north-marriott-hotel-and-conference-center
(More hotel information can be obtained from this website.)

Government Room Rate

A block of sleeping rooms has been reserved at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD. The group rate is the prevailing government rate, currently $231 per night, for single occupancy, plus tax (currently 13%). Participants may make reservations by calling the hotel directly or online at https://aws.passkey.com/e/49189239. The room block will be in effect at the group rate until Tuesday, October 3, 2017, only or until full, whichever comes first. Any room reservations received after that date will be accepted on a space- and rate-availability basis. Check-in time is 4:00 p.m., and checkout time is 12:00 p.m. Any reservation cancellations must be made prior to 4:00 p.m. the day before the scheduled arrival date, or charges will apply.


Please be certain that the hotel provides you with a confirmation number for your reservation. After October 3, 2017, the official room block will be released, and the hotel may charge significantly higher rates and may be sold out. When making a reservation, please provide your room and bedding preferences. The hotel will assign specific room types at check-in, based on availability. Please be advised that requests are not guaranteed. Check-in time is 4:00 p.m., and checkout time is 12:00 p.m.​


Minutes are currently unavailable.


Attendees are currently unavailable.


Submission Deadline: TBA

All abstracts must be submitted via email to Ms. LaKia Thomas, thomaslac@mail.nih.gov, with “Tolerance T1D” in the subject line. Abstract submissions should be no longer than 250 words (not including name and affiliation). Attach the abstract as a Microsoft Word document, and make any relevant comments in the text of the email.

Please follow the instructions below to format an abstract. (Note: Submissions will not be edited for spelling or grammar and will be accepted “as is.”)

  1. The abstract title should be typed in bold font, Title Case Letters (i.e., first letter of each main word capitalized).
  2. List the names, degrees, and institutional affiliations of all authors, and underline the name of the presenting author.
  3. Use 1” margins.
  4. The abstract should not exceed one page.
  5. Simple tables or graphs may be included; however, they must fit within the designated abstract space.
  6. Please use a common font, such as Calibri, Times New Roman, or Arial.
  7. Save the abstract file as: primary authors’ last name_first word in the title (e.g., Smith_AutoAntigens).


  • 5701 Marinelli Road
  • MD 20852


Line ​​Program Content
Lisa Spain, Ph.D.
T: 301-451-9871
E: spainl@mail.nih.gov

Meeting Logistics

John Hare
The Scientific Consulting Group, Inc.
T: 301-670-4990
E: jhare@scgcorp.com